393 related articles for article (PubMed ID: 17075881)
1. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
Saadoun D; Resche-Rigon M; Thibault V; Piette JC; Cacoub P
Arthritis Rheum; 2006 Nov; 54(11):3696-706. PubMed ID: 17075881
[TBL] [Abstract][Full Text] [Related]
2. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.
Terrier B; Saadoun D; Sène D; Sellam J; Pérard L; Coppéré B; Karras A; Blanc F; Buchler M; Plaisier E; Ghillani P; Rosenzwajg M; Cacoub P
Arthritis Rheum; 2009 Aug; 60(8):2531-40. PubMed ID: 19644879
[TBL] [Abstract][Full Text] [Related]
4. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
Mazzaro C; Zorat F; Caizzi M; Donada C; Di Gennaro G; Maso LD; Carniello G; Virgolini L; Tirelli U; Pozzato G
J Hepatol; 2005 May; 42(5):632-8. PubMed ID: 15826710
[TBL] [Abstract][Full Text] [Related]
5. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
[TBL] [Abstract][Full Text] [Related]
6. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
Saadoun D; Resche Rigon M; Sene D; Terrier B; Karras A; Perard L; Schoindre Y; Coppéré B; Blanc F; Musset L; Piette JC; Rosenzwajg M; Cacoub P
Blood; 2010 Jul; 116(3):326-34; quiz 504-5. PubMed ID: 20439619
[TBL] [Abstract][Full Text] [Related]
7. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.
Saadoun D; Resche Rigon M; Thibault V; Longuet M; Pol S; Blanc F; Pialoux G; Karras A; Bazin-Karra D; Cazorla C; Vittecoq D; Musset L; Decaux O; Ziza JM; Lambotte O; Cacoub P
Ann Rheum Dis; 2014 May; 73(5):831-7. PubMed ID: 23606708
[TBL] [Abstract][Full Text] [Related]
8. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
[TBL] [Abstract][Full Text] [Related]
9. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
Dammacco F; Tucci FA; Lauletta G; Gatti P; De Re V; Conteduca V; Sansonno S; Russi S; Mariggiò MA; Chironna M; Sansonno D
Blood; 2010 Jul; 116(3):343-53. PubMed ID: 20308602
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
11. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P
J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864
[TBL] [Abstract][Full Text] [Related]
12. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.
Landau DA; Saadoun D; Halfon P; Martinot-Peignoux M; Marcellin P; Fois E; Cacoub P
Arthritis Rheum; 2008 Feb; 58(2):604-11. PubMed ID: 18240235
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study.
Mazzaro C; Monti G; Saccardo F; Zignego AL; Ferri C; De Vita S; Gabrielli A; Lenzi M; Donada C; Galli M; Pietrogrande M; Pozzato G
Clin Exp Rheumatol; 2011; 29(6):933-41. PubMed ID: 22153224
[TBL] [Abstract][Full Text] [Related]
14. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
16. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
17. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
18. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
20. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
Saracco G; Olivero A; Ciancio A; Carenzi S; Smedile A; Cariti G; Andreoni M; Orsi PG; Biglino A; Tabone M; Roffi L; Croce G; Manca A; Tappero G; Ciccone G; Rizzetto M
Hepatology; 2002 Oct; 36(4 Pt 1):959-66. PubMed ID: 12297844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
